Base de datos - (CIANE) | |
Presentación de esta base de datos documental (Sitio web de CIANE) |
https://ciane.net/id=2804 | ➡ Editar este registro |
Ficha bibliográfica (sin autores) : | Off-label use of misoprostol for labor induction in Germany: A national survey - European Journal of Obstetrics Gynecology and Reproductive Biology - Vol. 187 - p.85-89 |
Autores : | Voigt, F.; Goecke, T.W.; Najjari, L.; Pecks, U.; Maass, N.; Rath, W. |
Año de publicación : | 2015 |
URL(s) : | https://www.scopus.com/inward/record.uri?eid=2-s2.… |
Résumé (français) : |
|
Abstract (English) : | Objective Misoprostol is safe and effective for labor induction in viable pregnancies. Little is known about the prevalence of off-label use of misoprostol, and the reasons for using or not using misoprostol for labor induction. As such, a national survey was conducted in Germany to assess reliable data about the use of misoprostol in clinical practice. Study design A prospective study was performed in 2013 using a standardized survey questionnaire. All registered departments of obstetrics and gynecology in Germany were targeted. Results Out of 783 questionnaires, 542 (69%) were returned. Three hundred and fifty-five (66%) respondents reported that they use misoprostol for labor induction in viable term pregnancies, and 183 (34%) respondents reported that they never use misoprostol for this indication. The most common reasons given for using misoprostol in labor induction were: effectiveness (40%), good patient acceptance (35%), established/well proven in clinical practice (35%) and cost-effectiveness (32%). The most common reasons given for not using misoprostol were lack of licence (off-label use, 69%) and uncertainty of the legal situation (27%). Conclusion Although misoprostol is not licensed in Germany for obstetric indications, the vast majority of respondents (66%) reported that they use misoprostol for labor induction. The main reasons for not using misoprostol for labor induction in Germany are legal concerns rather than lack of scientific evidence. Cost-effective medications with evidence-based effectiveness and safety should be supported by a clear statement from national medical societies. © 2014 Elsevier Ireland Ltd. |
Sumário (português) : |
|
Resumen (español) : | |
Comentarios : | |
Argument (français) : |
|
Argument (English): |
|
Argumento (português): |
|
Argumento (español): | |
Palabras claves : | |
Autor de este registro : | Import 26/11/2017 — 26 Nov 2017 |
Debate (mostrar sólo español) | ||
---|---|---|
Realizar otra consulta de expertos --- Realice otra consulta sencilla
Creación de un registro --- Importación de registros
Gestión de usuarios --- Salvaguardar la base de datos --- Contacto
Esta base de datos creada por la Alliance francophone pour l'accouchement respecté (AFAR) está gestionada
por el Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
Se nutre de las contribuciones de voluntarios interesados en compartir información científica.
Si está de acuerdo con este proyecto, puede ayudarnos de varias maneras:
(1) convertirse en colaborador de esta base de datos, si tiene alguna experiencia en documentación
(2) ou apoio financeiro CIANE (veja abaixo)
(3) o hacerse miembro de otra asociación afiliada al CIANE.
➡ Inicie sesión o cree una cuenta para seguir los cambios o convertirse en editor.
➡ Contacta con bibli(arobase)ciane.net para más información.
Donar a CIANE (haga clic en 'Faire un don') nos ayudará a mantener y desarrollar sitios y bases de datos públicas para apoyar las decisiones informadas de los progenitores y profesionales de la salud con respecto al parto |